WELLS FARGO & COMPANY/MN - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 96 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q4 2014. The put-call ratio across all filers is 1.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$3,000
-92.1%
5,244
-81.2%
0.00%
Q1 2019$38,000
+22.6%
27,967
+0.1%
0.00%
Q4 2018$31,000
-60.3%
27,934
-0.6%
0.00%
Q3 2018$78,000
-15.2%
28,095
+8.8%
0.00%
Q2 2018$92,000
-5.2%
25,819
-18.7%
0.00%
Q1 2018$97,000
-47.8%
31,776
+7.5%
0.00%
Q4 2017$186,000
-36.7%
29,555
-31.4%
0.00%
Q3 2017$294,000
+9.7%
43,069
+14.2%
0.00%
Q2 2017$268,000
-60.5%
37,704
-48.9%
0.00%
Q1 2017$678,000
+18.5%
73,765
-48.0%
0.00%
Q4 2016$572,000
+940.0%
141,966
+895.6%
0.00%
Q3 2016$55,000
-11.3%
14,259
-1.0%
0.00%
Q2 2016$62,000
-24.4%
14,402
-18.3%
0.00%
Q1 2016$82,000
-45.7%
17,628
+17.5%
0.00%
Q4 2015$151,000
-4.4%
15,008
-29.1%
0.00%
Q3 2015$158,000
-98.5%
21,166
-90.8%
0.00%
-100.0%
Q2 2015$10,882,000
-27.0%
229,396
-43.6%
0.00%
+33.3%
Q1 2015$14,910,000
+190.2%
406,932
+214.6%
0.00%
+50.0%
Q4 2014$5,137,000
+16.7%
129,355
-41.4%
0.00%0.0%
Q3 2014$4,403,000
-8.1%
220,711
-37.9%
0.00%0.0%
Q2 2014$4,793,000
+14.7%
355,294
-7.4%
0.00%0.0%
Q1 2014$4,177,000
+14.4%
383,615
+42.0%
0.00%0.0%
Q4 2013$3,652,000270,1290.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q4 2014
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 354,300$7,068,0002.77%
Opaleye Management Inc. 169,700$3,385,515,0002.64%
Broadfin Capital, LLC 959,247$19,137,0002.01%
Novo Holdings A/S 900,000$17,955,0001.75%
Eventide Asset Management 300,900$6,003,0000.84%
EAM Investors, LLC 152,595$3,044,0000.62%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 497,858$9,932,0000.51%
Granite Point Capital Management, L.P. 40,000$798,0000.40%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 450,191$8,981,0000.33%
TFS CAPITAL LLC 133,070$2,655,0000.23%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders